Previous close | 945.60 |
Open | 951.60 |
Bid | 967.60 x 0 |
Ask | 969.60 x 0 |
Day's range | 951.60 - 951.60 |
52-week range | 951.60 - 951.60 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.